UY29401A1 - Clorhidato de lercanidipina amorfo. - Google Patents

Clorhidato de lercanidipina amorfo.

Info

Publication number
UY29401A1
UY29401A1 UY29401A UY29401A UY29401A1 UY 29401 A1 UY29401 A1 UY 29401A1 UY 29401 A UY29401 A UY 29401A UY 29401 A UY29401 A UY 29401A UY 29401 A1 UY29401 A1 UY 29401A1
Authority
UY
Uruguay
Prior art keywords
lercanidipine
chlorhidate
amorfo
pure
amorphous lercanidipine
Prior art date
Application number
UY29401A
Other languages
English (en)
Inventor
Fabio Berlati
Amadeo Leonardi
Gianni Motta
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36585434&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29401(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of UY29401A1 publication Critical patent/UY29401A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C07B63/04—Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona un clorhidrato de lercanidipina amorfo sustancialmente puro con una pureza de por lo menos 95%, preferentemente por lo menos aproximadamente 97% puro, más preferentemente por lo menos aproximadamente 99% puro, y aun más preferentemente por lo menos aproximadamente 99,5% puro. La invención proporciona además métodos para preparar lercanidipina amorfo sustancialmete pura, y composiciones farmacéuticas que contienen la lercanidipina amorfo sustancialmente pura.
UY29401A 2005-02-25 2006-02-24 Clorhidato de lercanidipina amorfo. UY29401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65683605P 2005-02-25 2005-02-25

Publications (1)

Publication Number Publication Date
UY29401A1 true UY29401A1 (es) 2006-06-30

Family

ID=36585434

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29401A UY29401A1 (es) 2005-02-25 2006-02-24 Clorhidato de lercanidipina amorfo.

Country Status (32)

Country Link
US (1) US7820701B2 (es)
EP (1) EP1856051B1 (es)
JP (1) JP2008531515A (es)
KR (1) KR20070105979A (es)
CN (1) CN101124204A (es)
AR (1) AR052918A1 (es)
AU (1) AU2006218026B9 (es)
BR (1) BRPI0608138A2 (es)
CA (1) CA2598016A1 (es)
CY (1) CY1122429T1 (es)
DK (1) DK1856051T3 (es)
EA (1) EA014383B1 (es)
ES (1) ES2339213T3 (es)
HR (1) HRP20192302T1 (es)
HU (1) HUE046910T2 (es)
IL (1) IL184349A0 (es)
LT (1) LT1856051T (es)
ME (1) ME03659B (es)
MX (1) MX2007010093A (es)
MY (1) MY142129A (es)
NO (1) NO344559B1 (es)
NZ (1) NZ556667A (es)
PE (1) PE20061014A1 (es)
PL (1) PL1856051T3 (es)
PT (1) PT1856051T (es)
RS (1) RS59654B1 (es)
SI (1) SI1856051T1 (es)
TW (1) TW200640861A (es)
UA (1) UA90130C2 (es)
UY (1) UY29401A1 (es)
WO (1) WO2006089787A1 (es)
ZA (1) ZA200708127B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011647A1 (en) * 2002-07-26 2004-02-05 Chiron Corporation Modified small interfering rna molecules and methods of use
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
WO2007031865A2 (en) 2005-09-16 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
DK2046745T3 (da) * 2006-08-04 2014-01-20 Recordati Ireland Ltd Fremgangsmåde til fremstilling af amorft lercanidipin-hydrochlorid
WO2008068777A2 (en) * 2006-12-06 2008-06-12 Torrent Pharmaceuticals Limited Stable lercanidipine formulation
CN101868442A (zh) * 2007-03-05 2010-10-20 阿克塔维什集团Ptc公司 盐酸乐卡地平多晶型物和1,1,n-三甲基-n-(3,3-二苯基丙基)-2-氨基乙酰醋酸乙酯的改进制法
WO2010132445A1 (en) * 2009-05-12 2010-11-18 Corcept Therapeutics, Inc. Solid forms and process for preparing
DE102010005124A1 (de) * 2010-01-19 2012-03-01 Stada Arzneimittel Ag Feste pharmazeutische Zusammensetzung umfassend Lercanidipin
EP2444394A1 (en) 2010-10-21 2012-04-25 Alembic Pharmaceuticals Limited Process for the preparation of amorphous form of lercanidipine HCI
CN102558032B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 一种无定形盐酸乐卡地平及其制备方法
CN102531999B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 无定形盐酸乐卡地平及其制备方法
CN102600146B (zh) * 2012-04-11 2014-10-08 兆科药业（合肥）有限公司 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
MX371021B (es) * 2013-08-29 2020-01-13 Cadila Healthcare Ltd Procedimiento para preparar saroglitazar o sus sales farmaceuticamente aceptables.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
IT1274480B (it) 1995-05-12 1997-07-17 Recordati Chem Pharm Procedimento migliorato per la preparazione della lercanidipina cloridrato
US5696139A (en) * 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
US5767136A (en) * 1995-05-12 1998-06-16 Recordati, S.A. Chemical And Pharmaceutical Company 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US20030069285A1 (en) * 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
ITMI20011727A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Solvati della lercanidipina cloridrato e nuove forme cristalline della lercanidipina cloridrato ottenute da essi
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
US20030180355A1 (en) * 2001-10-16 2003-09-25 Amedeo Leonardi Combination therapy for hypertension
US20040147566A1 (en) * 2002-10-16 2004-07-29 Amedeo Leonardi Lisinopril/lercanidipine combination therapy
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
TW200613275A (en) * 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
KR100651212B1 (ko) 2004-10-27 2006-12-01 제일약품주식회사 무정형 레르카니디핀의 제조방법
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
WO2007031865A2 (en) 2005-09-16 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
WO2007054969A2 (en) 2005-09-21 2007-05-18 Torrent Pharmaceuticals Limited Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride
DK2046745T3 (da) 2006-08-04 2014-01-20 Recordati Ireland Ltd Fremgangsmåde til fremstilling af amorft lercanidipin-hydrochlorid

Also Published As

Publication number Publication date
EA200701687A1 (ru) 2008-02-28
RS59654B1 (sr) 2020-01-31
PE20061014A1 (es) 2006-10-03
ES2339213T1 (es) 2010-05-18
WO2006089787A1 (en) 2006-08-31
AU2006218026B2 (en) 2009-04-02
MX2007010093A (es) 2007-10-12
DK1856051T3 (da) 2020-01-02
HRP20192302T1 (hr) 2020-03-06
US20060211742A1 (en) 2006-09-21
AR052918A1 (es) 2007-04-11
CN101124204A (zh) 2008-02-13
UA90130C2 (ru) 2010-04-12
LT1856051T (lt) 2020-01-10
ME03659B (me) 2021-01-20
MY142129A (en) 2010-09-30
HUE046910T2 (hu) 2020-04-28
EP1856051A1 (en) 2007-11-21
NO20074874L (no) 2007-11-26
JP2008531515A (ja) 2008-08-14
ZA200708127B (en) 2008-11-26
NO344559B1 (no) 2020-02-03
ES2339213T3 (es) 2020-05-28
IL184349A0 (en) 2007-10-31
AU2006218026A1 (en) 2006-08-31
PT1856051T (pt) 2020-01-07
PL1856051T3 (pl) 2020-05-18
TW200640861A (en) 2006-12-01
BRPI0608138A2 (pt) 2009-11-17
CA2598016A1 (en) 2006-08-31
AU2006218026B9 (en) 2011-10-27
CY1122429T1 (el) 2021-01-27
SI1856051T1 (sl) 2020-02-28
KR20070105979A (ko) 2007-10-31
US7820701B2 (en) 2010-10-26
EA014383B1 (ru) 2010-10-29
NZ556667A (en) 2009-10-30
EP1856051B1 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
UY29401A1 (es) Clorhidato de lercanidipina amorfo.
DK3219705T3 (da) Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
CL2007001830A1 (es) Compuestos derivados de isoindol; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de deterioro cognitivo, alzheimer, neurodegeneracion y demencia.
UA97502C2 (ru) Кристаллическая твердая основа разагилина
IL183237A0 (en) Polymorphs of memantine hydrochloride
ME02689B (me) Novi kristalni oblik iii agomelatina, postupak za njegovu pripremu i farmaceutski preparati istog
BRPI0509184A (pt) composições farmacêuticas
DK1845954T3 (da) Oralt opløsende sammensætning af olanzapin og donepzil
ME02026B (me) Novi kristalni v oblik agomelatina, postupak za njegovu proizvodnju i farmaceutske smiješe koje ga sadrže
BRPI0816553A2 (pt) "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"
SI1695709T1 (sl) Gama-d kristalna oblika hidroklorida ivabradina, postopek za njegovo pripravo in farmacevtski sestavki, ki ga vsebujejo
ECSP066822A (es) Macrólidos y métodos para producir los mismos
TW200738649A (en) Calcilytic compounds
MX2009011999A (es) Extruidos con enmascaramiento del sabor mejorado.
TW200730521A (en) Triazine compounds having amino-and carboxyl-containing substituents
BRPI0610156A2 (pt) forma micronizada de um composto, forma purificada i do composto, kit, padrão de referência, e, método de preparaçao de uma composição farmacêutica.
MX2009000767A (es) Sintesis de (2s,5r)-5-etinil-1-{n-(4-metil-1-(4-carboxi-piridin-2- il)piperidin-4-il)glicil}pirrolidina-2-carbonitrilo.
UY30023A1 (es) Nueva asociacion de un inhibidor de la corriente sinusal i, y de un inhibidor calcico y las composiciones farmaceuticas que la contienen
UY29400A1 (es) Base libre de lercanidipina.
AP2006003858A0 (en) New association of a sinus node if inhibitor and acalcium inhibitor, and pharmaceutical composition s containing it
AR069649A1 (es) 4-(2,3- difluoro-6-(2- fluoro-4- metil- fenilsulfanil)- fenil)- piperidina
ZA200805656B (en) Prodrug ER²-selective substances, methods for the production thereof and pharmaceutical compositions containing said compounds
BRPI0508279A (pt) composições de peróxido estabilizadas
CL2007003574A1 (es) 4-((1r,3r)-1-(3,5-difluorofenil)-3-(4-(3-etil-5-isopropil-4h-1,2,4-triazol-4-il)piperidin-1-il)butil)-1-(metilsulfonil)piperidina; su proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y su uso en el tratamiento de una
CR20140109S (es) Composiciones farmaceuticas estabilizadoras que comprenden fesoterodina

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20200618